Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China · Delayed Price · Currency is CNY 28.99
+1.08 (3.87%)
At close: Feb 13, 2026
SHE:300878 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 127.48 | 347.01 | 514.56 | 529.41 | 631.18 | 621.79 |
Other Revenue | 4.19 | 4.19 | 5.07 | 3.03 | 1.77 | 0.98 |
| 131.67 | 351.2 | 519.62 | 532.44 | 632.95 | 622.77 | |
Revenue Growth (YoY) | -71.28% | -32.41% | -2.41% | -15.88% | 1.64% | -2.97% |
Cost of Revenue | 156.4 | 223.4 | 257.69 | 219.08 | 204.38 | 171.42 |
Gross Profit | -24.73 | 127.8 | 261.93 | 313.36 | 428.57 | 451.35 |
Selling, General & Admin | 170.67 | 261.73 | 249.42 | 230.39 | 294.74 | 298.07 |
Research & Development | 9.67 | 14.19 | 42.8 | 39.32 | 37.02 | 18.89 |
Other Operating Expenses | 5.46 | 10.23 | 1.07 | -17.9 | 4.8 | 3.47 |
Operating Expenses | 173.57 | 289.32 | 281.83 | 259.12 | 344.96 | 328.54 |
Operating Income | -198.3 | -161.53 | -19.9 | 54.24 | 83.62 | 122.8 |
Interest Expense | -10.79 | -9.34 | -9.45 | -5.41 | -2.16 | -0.25 |
Interest & Investment Income | 0.95 | 94.26 | 14.56 | 17.04 | 5.55 | 5.62 |
Other Non Operating Income (Expenses) | 4.17 | -0.07 | -0.09 | -0.16 | -0.09 | -0.06 |
EBT Excluding Unusual Items | -203.97 | -76.67 | -14.88 | 65.71 | 86.91 | 128.11 |
Impairment of Goodwill | -7.76 | -7.76 | -0.14 | -0.22 | -0.08 | - |
Gain (Loss) on Sale of Investments | - | - | 4.56 | - | - | - |
Gain (Loss) on Sale of Assets | -1.22 | -0.47 | -0.01 | -0.63 | 0.07 | -0 |
Asset Writedown | -96.99 | -76.26 | -0.52 | -0.18 | -0.02 | -0.01 |
Other Unusual Items | -4.18 | 2.89 | 4.3 | -1.52 | 13.16 | 30.6 |
Pretax Income | -314.12 | -158.28 | -6.68 | 63.15 | 100.03 | 158.7 |
Income Tax Expense | 0.79 | -13.4 | 0.42 | 13.67 | 3.48 | 23 |
Earnings From Continuing Operations | -314.91 | -144.88 | -7.1 | 49.48 | 96.55 | 135.7 |
Minority Interest in Earnings | -0.47 | -2.55 | -1.85 | -0.67 | -0.05 | 0.11 |
Net Income | -315.38 | -147.43 | -8.95 | 48.81 | 96.5 | 135.82 |
Net Income to Common | -315.38 | -147.43 | -8.95 | 48.81 | 96.5 | 135.82 |
Net Income Growth | - | - | - | -49.42% | -28.95% | 7.78% |
Shares Outstanding (Basic) | 143 | 143 | 149 | 144 | 144 | 120 |
Shares Outstanding (Diluted) | 143 | 143 | 149 | 144 | 144 | 120 |
Shares Change (YoY) | -4.22% | -4.09% | 3.96% | -0.32% | 19.60% | 10.96% |
EPS (Basic) | -2.20 | -1.03 | -0.06 | 0.34 | 0.67 | 1.13 |
EPS (Diluted) | -2.20 | -1.03 | -0.06 | 0.34 | 0.67 | 1.13 |
EPS Growth | - | - | - | -49.25% | -40.59% | -2.87% |
Free Cash Flow | -7.77 | -154.1 | -81 | -28.21 | -238.84 | -109.53 |
Free Cash Flow Per Share | -0.05 | -1.08 | -0.54 | -0.20 | -1.66 | -0.91 |
Dividend Per Share | 0.140 | 0.140 | 0.250 | - | 0.300 | 0.556 |
Dividend Growth | -44.00% | -44.00% | - | - | -46.00% | - |
Gross Margin | -18.78% | 36.39% | 50.41% | 58.85% | 67.71% | 72.47% |
Operating Margin | -150.60% | -45.99% | -3.83% | 10.19% | 13.21% | 19.72% |
Profit Margin | -239.53% | -41.98% | -1.72% | 9.17% | 15.25% | 21.81% |
Free Cash Flow Margin | -5.90% | -43.88% | -15.59% | -5.30% | -37.73% | -17.59% |
EBITDA | -131.3 | -103.25 | 26.75 | 84.04 | 97.65 | 134.97 |
EBITDA Margin | -99.72% | -29.40% | 5.15% | 15.78% | 15.43% | 21.67% |
D&A For EBITDA | 67 | 58.28 | 46.65 | 29.8 | 14.03 | 12.17 |
EBIT | -198.3 | -161.53 | -19.9 | 54.24 | 83.62 | 122.8 |
EBIT Margin | -150.60% | -45.99% | -3.83% | 10.19% | 13.21% | 19.72% |
Effective Tax Rate | - | - | - | 21.64% | 3.48% | 14.49% |
Revenue as Reported | 131.67 | 351.2 | 519.62 | 532.44 | 632.95 | 622.77 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.